These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 22343920)

  • 21. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
    Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
    Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
    Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
    Lindsley RC; Mar BG; Mazzola E; Grauman PV; Shareef S; Allen SL; Pigneux A; Wetzler M; Stuart RK; Erba HP; Damon LE; Powell BL; Lindeman N; Steensma DP; Wadleigh M; DeAngelo DJ; Neuberg D; Stone RM; Ebert BL
    Blood; 2015 Feb; 125(9):1367-76. PubMed ID: 25550361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
    Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
    Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.
    Wassie EA; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Solary E; Tefferi A; Patnaik MM
    Am J Hematol; 2014 Dec; 89(12):1111-5. PubMed ID: 25195656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
    Wong JJ; Lau KA; Pinello N; Rasko JE
    Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
    Volpe VO; Al Ali N; Chan O; Padron E; Sallman DA; Kuykendall A; Sweet K; Lancet JE; Komrokji RS
    Br J Haematol; 2022 Aug; 198(4):713-720. PubMed ID: 35751140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequent pathway mutations of splicing machinery in myelodysplasia.
    Yoshida K; Sanada M; Shiraishi Y; Nowak D; Nagata Y; Yamamoto R; Sato Y; Sato-Otsubo A; Kon A; Nagasaki M; Chalkidis G; Suzuki Y; Shiosaka M; Kawahata R; Yamaguchi T; Otsu M; Obara N; Sakata-Yanagimoto M; Ishiyama K; Mori H; Nolte F; Hofmann WK; Miyawaki S; Sugano S; Haferlach C; Koeffler HP; Shih LY; Haferlach T; Chiba S; Nakauchi H; Miyano S; Ogawa S
    Nature; 2011 Sep; 478(7367):64-9. PubMed ID: 21909114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts.
    Seo JY; Lee KO; Kim SH; Kim K; Jung CW; Jang JH; Kim HJ
    Ann Hematol; 2014 Apr; 93(4):603-8. PubMed ID: 24141330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.
    Madan V; Li J; Zhou S; Teoh WW; Han L; Meggendorfer M; Malcovati L; Cazzola M; Ogawa S; Haferlach T; Yang H; Koeffler HP
    Am J Hematol; 2020 Feb; 95(2):133-143. PubMed ID: 31680297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.
    Qiu J; Zhou B; Thol F; Zhou Y; Chen L; Shao C; DeBoever C; Hou J; Li H; Chaturvedi A; Ganser A; Bejar R; Zhang DE; Fu XD; Heuser M
    RNA; 2016 Oct; 22(10):1535-49. PubMed ID: 27492256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
    Kanagal-Shamanna R; Montalban-Bravo G; Sasaki K; Darbaniyan F; Jabbour E; Bueso-Ramos C; Wei Y; Chien K; Kadia T; Ravandi F; Borthakur G; Soltysiak KA; Routbort M; Patel K; Pierce S; Medeiros LJ; Kantarjian HM; Garcia-Manero G
    Cancer; 2021 Oct; 127(19):3552-3565. PubMed ID: 34161603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
    Richardson DR; Swoboda DM; Moore DT; Johnson SM; Chan O; Galeotti J; Esparza S; Hussaini MO; Van Deventer H; Foster MC; Coombs CC; Montgomery ND; Sallman DA; Zeidner JF
    Am J Hematol; 2021 Apr; 96(4):462-470. PubMed ID: 33502020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Qian J; Yao DM; Lin J; Qian W; Wang CZ; Chai HY; Yang J; Li Y; Deng ZQ; Ma JC; Chen XX
    PLoS One; 2012; 7(9):e45760. PubMed ID: 23029227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
    Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
    Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.